NMR Selectivity/Reversibility Experiments. 125 L of a CBT-OH stock solution (40 mg/mL in d 6 -DMSO) was added to 360 L of an NAC solution (1.1 equiv. NAC, 14 mg/mL in CD 3 OD) and allowed to equilibrate ([CBT-OH] = 59 mM, [NAC] = 64 mM). The changes in the NMR spectrum are observed after 15 minutes, and no further changes in the spectrum were observed after 6 hours. After equilibrium was reached, 100 L of L-cysteine (1 equiv., 34 mg/mL in D 2 O) was added, and an NMR spectrum was taken immediately ( For the GSH experiments the experimental parameters had to be modified to ensure solubility. 125 L of the CBT-OH stock solution were added to a mixture of 250 L of d 6 -DMSO and 360 L of a GSH solution (1.1 equiv. GSH, 26.4 mg/mL in D 2 O) and allowed to equilibrate ([CBT-OH] = 39 mM, [GSH] = 43 mM]). The changes in the NMR spectrum were observed after 15 minutes, and no further changes were observed after 1.5 hours as shown in spectrum (d). After equilibration, 100 mL of cysteine solution (1 equiv.) were added ([CBT-OH] = 34 mM, [GSH] = 38 mM, [cysteine] = 34 mM). After 7 hours no further change in the NMR spectrum were observed, presumably due to the complete oxidation of any remaining free thiols. This conclusion is supported by the disappearance of the triplet peak at 4.62 ppm in spectrum (d) and the new appearance of the quartet at 4.75 ppm in spectrum (e), which agrees with the literature value for GSSG. Addition of another 100 mL of cysteine solution and 200 mL of d 6 -DMSO results in a simultaneous increase in the luciferin peaks with a corresponding decrease in remaining CBT-OH speaks as seen in spectrum (f) ([CBT-OH] = 25 mM, [GSH] = 28 mM, [cysteine] = 50 mM).
UV-Vis Kinetic Measurements.
A 10 mM stock solution of CBT-OH was prepared in DMSO, and a 100 mM solution of L-cysteine was prepared in tris buffer. The CBT-OH solution was diluted to 25 M in 3 mL of tris buffer. The desired amount of cysteine (250, 375, or 500 M) was then added to the cuvette, and absorbance measurements were made at 366 nm every 0.05 s for up to 20 min. Each cysteine concentration was repeated in triplicate, and the data were fit directly to an exponential growth curve.
Bioluminescence Detection. CBT-OH (100 M) and D-cysteine (1-20 M) were incubated for 1 hour in tris buffer. Luciferin formation was measured by adding 0.1 mg/mL luciferase in tris buffer with 10 mM MgSO 4 , 2 mM ATP, 0.1 mM DAO, 40 M FAD. The bioluminescent signal at 560 nm was integrated for 45 min.
DAO Activity Assay. D-cysteine (20 M) was added to 0.1 mg/mL DAO in Tris buffer with 40 M FAD. At different time points (0, 30, 60, 90 , 120, and 300 s) CBT-OH (100 M) was added to the solution and the mixture was incubated at 37 °C for 1 hour. Luciferin formation was detected by adding 0.1 mg/mL luciferase in tris buffer (pH 7.4, 50 mM) with 10 mM MgSO 4 , 2 mM ATP. Bioluminescent signal at 560 nm was integrated for 45 min. Negative controls followed the same method in the absence of DAO or using 20 M L-cysteine instead of Dcysteine. Inhibition or competition experiments included the addition of either 2 M sodium benzoate or 20 M D-serine, respectively. Figure S1 . (a) The UV-vis absorbance spectra of 50 M CBT-OH (black) and D-luciferin (red). (b) The reaction of 25 M CBT-OH with 375 M D-cysteine monitored at 366 nm for 15 min with data collected every 0.05 s. The data were fit directly to an exponential growth function to obtain the pseudo-first order rate constant. Figure S2 . Plot of pseudo-first order rate constant (k obs ) with respect to cysteine concentration. Each point is the average of three independent runs. Error bars represent the standard deviation of the data. The slope of the line is the overall second order rate constant for the reaction. Figure S3 . Selectivity of CBT-OH for Cys over GSH. (a) CBT-OH reacts reversibly with GSH and irreversibly with cysteine.
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NMR Selectivity Data
1 H NMR spectra (500 MHz, d 6 -DMSO/D 2 O mixture, room temperature) of (b) CBT-OH and (c) GSH; (d) after 1.5 hr; (e) after 7 hours with 1 equiv of cysteine; (f) after the addition of an additional equivalent of cysteine.
